CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 222 enrolled
Drug / intervention
insulin degludec +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01326026
NCT01326026Phase 3Completed
CompareCT.gov

A Trial Comparing the Efficacy and Safety of Insulin Degludec Once Daily in Insulin naïve Subjects With Type 2 Diabetes Mellitus When Titrated Using Two Different Titration Algorithms (BEGIN™: ONCE SIMPLE USE)

Novo Nordisk A/S·interventional·Posted Mar 30, 2011·Updated Mar 6, 2017

In Brief

A Phase 3 clinical trial evaluating insulin degludec for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 222 participants across 45 sites in 4 countries.

Detailed Summary

This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) once daily in insulin naïve subjects with type 2 diabetes mellitus when titrated using two different self-titration algorithms (dose individually adjusted) in combination with metformin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesFinland, Germany, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 30, 2011
Enrollment StartMar 1, 2011
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.3 years ago

Interventions

insulin degludecdrug

Injected subcutaneously (under the skin) once daily. Dose individually adjusted.

insulin degludecdrug

Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.